Lavipharm S.A. Logo

Lavipharm S.A.

Develops & distributes Rx/OTC medicines, supplements & cosmetics for key therapeutic areas.

LAVI | AT

Overview

Corporate Details

ISIN(s):
GRS246003008
LEI:
213800USC69CRPRGWJ15
Country:
Greece
Address:
AGIAS MARINAS STR, 19002 PAIANIA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Lavipharm S.A. is an integrated international healthcare company focused on the research, development, manufacturing, marketing, and distribution of pharmaceutical products. The company's portfolio includes prescription (Rx) and over-the-counter (OTC) medicines, as well as food supplements and cosmetics. Lavipharm provides innovative treatment options to healthcare professionals, concentrating on key therapeutic areas such as cardiology, neurology (CNS), urology, oncology, and chronic pain. The company manages the entire value chain, from initial research and development to commercial sales and distribution.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-18 19:39
Interim Report
Οικονομική έκθεση LAVIPHARM Α.Ε. (2025,Εξαμηνιαία,Ενοποιημένη)
Greek (modern) 2.2 MB
2025-09-18 16:50
Earnings Release
ΔΕΛΤΙO ΤΥΠΟΥ ΟΙΚΟΝΟΜΙΚΑ ΑΠΟΤΕΛΕΣΜΑΤΑ Α΄ ΕΞΑΜΗΝΟΥ 2025
Greek (modern) 156.3 KB
2025-09-18 16:50
Earnings Release
FINANCIAL RESULTS PRESS RELEASE FIRST HALF 2025
English 99.2 KB
2025-07-10 09:38
Registration Form
Έντυπο παροχής πληροφοριών Κανονισμού (ΕΕ) 2017/1129 (άρθρ. 1 παρ. 5 η’) αναφορ…
Greek (modern) 216.3 KB
2025-07-09 09:52
Share Issue/Capital Change
Έντυπο παροχής πληροφοριών Κανονισμού (ΕΕ) 2017/1129 (άρθρ. 1 παρ. 4 θ΄) αναφορ…
Greek (modern) 205.1 KB
2025-07-03 18:12
Notice of Dividend Amount
ΓΝΩΣΤΟΠΟΙΗΣΗ ΑΠΟΚΟΠΗΣ ΔΙΚΑΙΩΜΑΤΟΣ ΜΕΡΙΣΜΑΤΟΣ / ΠΛΗΡΩΜΗΣ ΜΕΡΙΣΜΑΤΟΣ/ ΠΡΟΜΕΡΙΣΜΑΤ…
Greek (modern) 555.0 KB
2025-07-03 18:00
Post-Annual General Meeting Information
ΔΕΛΤΙΟ ΤΥΠΟΥ ΓΕΝΙΚΗΣ ΣΥΝΕΛΕΥΣΗΣ
Greek (modern) 123.4 KB
2025-07-03 18:00
Post-Annual General Meeting Information
PRESS RELEASE
English 121.3 KB
2025-07-03 17:35
Post-Annual General Meeting Information
ΑΝΑΚΟΙΝΩΣΗ ΕΠΙΤΡΟΠΗΣ ΕΛΕΓΧΟΥ
Greek (modern) 503.0 KB
2025-07-03 17:17
Board/Management Information
ΓΝΩΣΤΟΠΟΙΗΣΗ ΑΛΛΑΓΗΣ ΣΥΝΘΕΣΗΣ ΔΙΟΙΚΗΤΙΚΟΥ ΣΥΜΒΟΥΛΙΟΥ
Greek (modern) 598.1 KB
2025-07-03 17:05
Post-Annual General Meeting Information
ΑΝΑΚΟΙΝΩΣΗ ΓΙΑ ΤΙΣ ΑΠΟΦΑΣΕΙΣ ΓΕΝΙΚΗΣ ΣΥΝΕΛΕΥΣΗΣ
Greek (modern) 195.1 KB
2025-06-11 16:30
Pre-Annual General Meeting Information
ΠΡΟΣΚΛΗΣΗ ΣΕ ΤΑΚΤΙΚΗ ΓΕΝΙΚΗ ΣΥΝΕΛΕΥΣΗ
Greek (modern) 191.0 KB
2025-05-15 16:19
Earnings Release
Βασικά Οικονομικά Μεγέθη A Τριμήνου 2025
Greek (modern) 118.2 KB
2025-05-15 16:19
Earnings Release
Financial Results Q1 2025
English 92.6 KB
2025-04-24 16:39
Investor Presentation
ΑΝΑΚΟΙΝΩΣΗ ΓΙΑ ΕΝΗΜΕΡΩΣΗ ΕΙΣΗΓΜΕΝΗΣ ΠΡΟΣ ΑΝΑΛΥΤΕΣ
English 1.0 MB

Automate Your Workflow. Get a real-time feed of all Lavipharm S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Lavipharm S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
MYUNGMOON PHARM CO.,LTD Logo
Develops, manufactures, and commercializes prescription & OTC medicines for global markets.
South Korea 017180
Nanexa AB Logo
Develops long-acting injectables using its proprietary nanotechnology for its own pipeline and partners.
Sweden NANEXA
Nanobiotix Logo
Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.
France NANO
Nanoform Finland OYJ Logo
Pharma tech firm engineering nanoparticles to enhance drug performance and development.
Finland NANOFH
NanoGroup S.A. Logo
Develops patented nanotechnology for oncology and transplantology diagnostics and therapies.
Poland NNG
NanoRepro AG Logo
Develops and distributes rapid diagnostic self-tests for early disease detection.
Germany NN6
NATAC Logo
Develops sustainable plant extracts for nutraceutical, pharma, food, and animal nutrition industries.
Spain NAT
Biotech R&D of natural ingredients for health and wellness solutions.
South Korea 168330
Naturland Holding PLC Logo
A Hungarian company providing full-scale pharmaceutical manufacturing from R&D to sales.
United Kingdom NATUR
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America 950220

Talk to a Data Expert

Have a question? We'll get back to you promptly.